Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319940 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
A Phase 1 study of Small Cell Lung Carcinoma, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 269
- Enrollment target
- 20
- Study locations
NCT03319940: Active Phase 1 study of Small Cell Lung Carcinoma, sponsored by Amgen.
NCT03319940 is a Phase 1 study of Small Cell Lung Carcinoma that is active but no longer recruiting, run by Amgen. The registered enrollment target is 269 participants, roughly in line with the 246-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03319940, a Phase 1 study of Small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 269 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Tarlatamab
- DRUG CRS Mitigation Strategies
Study Locations (20)
Other
- Medizinische Universitaet Graz - Graz
- Landeskrankenhaus Salzburg - Salzburg
- Gustave Roussy - Villejuif
- Universitaetsklinikum Wuerzburg - Würzburg
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic - Columbus
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center Cancer Pavillion - Pittsburgh
California
- City of Hope National Medical Center - Duarte
Connecticut
- Yale New Haven Hospital - New Haven
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute - Atlanta
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2017-12-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What the registry record for NCT03319940 still lists
NCT03319940 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 246-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target.
The record links to 1 condition, with Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03319940 names 20 study sites across 15 states, led by Other, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03319940 about?
NCT03319940 is a clinical study titled "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)". A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
What is the current status of trial NCT03319940?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 269 participants. The study started on 2017-12-26. Estimated completion is 2027-12-31.
What conditions does trial NCT03319940 study?
This clinical trial studies the following conditions: Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT03319940?
The interventions under investigation include: Pembrolizumab (DRUG), Tarlatamab (DRUG), CRS Mitigation Strategies (DRUG).
Who is sponsoring clinical trial NCT03319940?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03319940 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03319940's enrollment target sits among peer trials
269 5th of 18 higher than 14 of 18 other Small Cell Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
RECRUITING · Phase 1
-
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI